SUMO-1 (human), (recombinant) (Histag)

SUMO (small ubiquitin-related modifier) is a member of a family of ubiquitin-like proteins involved in the regulation of the cellular functions of a wide variety of proteins. Four members of the SUMO family have been described in vertebrates, SUMO-1 and the close homologues SUMO-2 and SUMO-3, with some 50% homology between SUMO-1 and SUMO-2/3. Although a fourth SUMO (SUMO-4) has been reported, there remains considerable debate as to whether this is a real and expressed gene product.

The mechanism for SUMO conjugation is analogous to that of the ubiquitin system, relying upon utilisation of E1, E2 and (potentially) E3 cascade enzymes to covalently link the carboxy-terminal of SUMO proteins to specific lysine residues on target proteins via isopeptide bonds. Unlike ubiquitinylation, which leads, *inter alia*, to a degradative pathway, SUMO modification of target proteins is involved in nuclear protein targeting, formation of sub-nuclear complexes, regulation of transcriptional activities, and control of protein stability. A short sequence containing the consensus Ψ -K-X-D/E (where lysine is the modified amino acid, Ψ is a large hydrophobic residue and X is any amino acid residue) is thought to be necessary for protein SUMOylation to occur, however, SUMOylation has also been observed in cases where the consensus site is not conserved.

Conjugation of mature SUMO proteins to specific lysine residues on target proteins via isopeptide bonds, is involved in a range of processes including nuclear protein targeting, formation of sub-nuclear complexes, regulation of transcriptional activities, and control of protein stability.

Citations: 9

View Online »

Ordering Information

Order Online »

BML-UW9195-0500

500µg

Manuals, SDS & CofA

View Online »

SUMOylation Assay



SUMOylation assays for RANGAP1 target protein using SUMO-1, 2 and 3. SUMOylated proteins were detected by Western blotting using the appropriate BIOMOL SUMO antibodies. Results demonstrate the formation of SUMOylated target proteins of the expected size in all ATP containing reactions (+). The absence of such conjugates in negative control reactions (–) demonstrates that their formation is ATP dependent (required for E1 activation) and hence derived from the SUMO cascade.

Coomassie



SDS-PAGE Analysis of SUMO-1 protein. Lane 1: MW markers (top to bottom) 66, 45, 36, 29, 24, 20 and 16. Lane 2: 10µg SUMO-1. Protein runs at ~20kDa.

Handling & Storage

Handling Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80°C.

Long Term Storage -80°C

Shipping Dry Ice

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name Sentrin-1, Small ubiquitin-related modifier 1

Application NotesIn the presence of HeLa Fraction II or a combination of

SUMO E1 and E2 (Prod. No. BML-UW9330 and BML-UW9320 respectively), with ATP, Mg²⁺, and DTT, mature SUMO-1 may be conjugated to soluble proteins. Typical *in vitro* concentration for non-rate limiting conjugate formation

is 200µM to 1mM, depending upon conditions.

Uses:

1. SUMO-1 modification of specific proteins in vitro.

2. Demonstrate novel proteins are potential targets for

SUMOylation under in vitro conditions.

3. Generate substrates for deSUMOylating enzymes.

Formulation Liquid. In HEPES, pH 8.0, containing 50mM NaCl, 1mM

DTT.

MW ~12kDa

Purity ≥95% (SDS-PAGE)

Source Produced in *E. coli*. Human SUMO-1 is fused to a His-tag.

UniProt ID P63165

Last modified: May 29, 2024



ENZO LIFE SCIENCES, INC. Phone: 800.942.0430 infousa@enzolifesciences.com European Sales Office ENZO LIFE SCIENCES (ELS) AG Phone: +41 61 926 8989 infoeu@enzolifesciences.com Belgium, The Netherlands & Luxembourg Phone: +32 3 466 0420 infobe@enzolifesciences.com

France
Phone: +33 472 440 655
infofr@enzolifesciences.com

Germany
Phone: +49 7621 5500 526
infode@enzolifesciences.com

UK & Ireland
Phone (UK customers):
0845 601 1488
Phone: +44 1392 825900
infouk@enzolifesciences.com